Why invest in Royalty Pharma

A unique way to invest in biopharma

Key highlights

Market leader & pioneer

of compounding value
Share of pharmaceutical royalty market
Royalty acquisitions since founding

Significant funding opportunity

Capital required for biopharma innovation over next decade

Strong track record

Portfolio Receipts CAGR between 2010-2020

Efficient business model

Portfolio Receipts (2023)
EBITDA margin

Long duration, diversified portfolio

Portfolio duration with track record of growing through royalty expirations
Blockbuster products (>$1bn in annual sales)

Maximizing biopharma industry strengths and minimizing challenges



Investor resources

Watch our inaugural Investor Day 2022

Royalty Pharma Investor Day highlights stronger growth outlook and the power of our unique business model to drive value for all stakeholders.

Stay up to date

Subscribe to Royalty Pharma news and alerts